ACLX News and Press, Arcellx Inc. From 12/08/23

2023-12-08 16:43:19 ET Gainers: IGM Biosciences, Inc. ( IGMS ) +9% . EF Hutton Acquisition Corporation I ( EFHT ) +6% . Biomea Fusion ( BMEA ) +5% . Larimar Therapeutics ( LRMR ) +2% . First Solar ( FSLR ) +1% . Losers: L...

Arcellx Announces Continued Robust Long-Term Responses from Its CART-ddBCMA (anito-cel) Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at ASH PR Newswire -- Median duration of response, progression free survival, and overall survival rate not re...

2023-11-19 12:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-11-15 13:44:49 ET Summary Arcellx's CART-ddBCMA reported strong and competitive data in late-line multiple myeloma patients, positioning it well against CAR-T leader Carvykti. The updated data at ASH show that the efficacy held up and even slightly improved compared to the pr...

2023-11-15 07:00:00 ET Summary Biotech stocks, long burdened by concerns over rising yields, are poised for improvement as the 10-year yield may have peaked, signaling a potential upswing in the industry's fortunes. The recent uptrend in the 10-year yield, peaking around 5% in Oct...

2023-11-15 06:39:59 ET More on Arcellx Arcellx: Clinical Hold Lifted, Charting A Brighter Path Forward (Rating Upgrade) Arcellx jumps after data for Gilead-partnered multiple myeloma drug Seeking Alpha’s Quant Rating on Arcellx Historical earnings data...

ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP PR Newswire -- Arcellx to receive $200M equity investment at $61.68 per share and an $85 million upfront cash payment -- -- Kite exercises option to Arcellx's ARC-SparX program ACLX-001 in multiple myel...

-- The companies expand the scope of their existing collaboration for CART-ddBCMA to include lymphomas -- -- Kite exercises option to Arcellx’s ARC-SparX program ACLX-001 in multiple myeloma -- -- Arcellx to receive $200M equity investment at $61.68 per share and an $85 mil...

2023-11-14 01:59:56 ET More on Arcellx Arcellx: Clinical Hold Lifted, Charting A Brighter Path Forward (Rating Upgrade) Arcellx jumps after data for Gilead-partnered multiple myeloma drug Seeking Alpha’s Quant Rating on Arcellx Historical earnings data...

Arcellx Provides Third Quarter 2023 Financial Results and Business Highlights PR Newswire -- Recently released ASH abstract for the company's Phase 1 CART-ddBCMA trial demonstrated that median duration of response, progression free survival, and overall survival not reached...